Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 12-Month Low – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX) reached a new 52-week low during trading on Tuesday . The stock traded as low as $7.39 and last traded at $7.4390, with a volume of 31094 shares trading hands. The stock had previously closed at $7.58.

Wall Street Analysts Forecast Growth

TLX has been the subject of several research analyst reports. Citigroup began coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They issued a “buy” rating and a $22.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Monday, December 22nd. UBS Group cut their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Trading Up 1.7%

The business’s fifty day moving average price is $9.04 and its 200-day moving average price is $11.04.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several large investors have recently modified their holdings of TLX. JPMorgan Chase & Co. purchased a new position in shares of Telix Pharmaceuticals during the 3rd quarter valued at $243,000. Millennium Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the third quarter worth approximately $1,883,000. Lazard Asset Management LLC purchased a new position in Telix Pharmaceuticals in the 3rd quarter worth about $1,097,000. Portland Investment Counsel Inc. purchased a new position in shares of Telix Pharmaceuticals during the third quarter worth approximately $1,225,000. Finally, Private Advisor Group LLC lifted its holdings in shares of Telix Pharmaceuticals by 67.3% in the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock worth $403,000 after buying an additional 16,945 shares during the period.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.